Clinical trial

AIManage Using an AI-driven CDS and Chatbot

Opening soon · Not applicable · 1 countries · Registry ID NCT07546357

Opening soonNot applicableInterventional

What this study is about

The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH. The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionDiabetes, Obesity, Medication Side Effects

Full registry criteria

Inclusion Criteria: Provider Eligibility Criteria (Phase 1) * Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics, * Provide care to at least 5 patients prescribed an IMM. Patient Eligibility Criteria (Phase 1) * (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months; * Fluency in English or Spanish; * Be willing to send/receive text messages; and * Be \> 18 years of age. Exclusion Criteria: Provider Exclusion Criteria (Phase 1) • Refuse to participate Patient Exclusion Criteria (Phase 1) • Refuse or are unable to provide informed consent;

Treatments and study arms

AIManage

Other

GenAI-powered CDS tool that provides a range of IMM management services, such as personalized guidance for patients on side effects management and clinical advisement to optimize dose titrations.

Primary outcomes

Percentage of Patients who Complete Qualitative Measure - Perceived UsefulnessDay 1 (60 minutes)

In Phase 1, qualitative data regarding perceived usefulness will be collected.

Percentage of Patients who Complete Qualitative Measure - Perceived UsabilityDay 1 (60 minutes)

In Phase 1, qualitative data regarding perceived usability will be collected.

Percentage of Patients who Complete Qualitative Measure - Perceived Use ChallengesDay 1 (60 minutes)

In Phase 1, qualitative data regarding perceived use challenges will be collected.

Percentage of Patients who Complete Qualitative Measure - Perceived ValueDay 1 (60 minutes)

In Phase 1, qualitative data regarding perceived value will be collected.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

NYU Langone Health🇺🇸 New York, New York, United States

Open map